Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

Conditions:   Breast Cancer Female;   Hormone Receptor Positive Malignant Neoplasm of Breast Interventions:   Drug: Palbociclib;   Drug: Endocrine therapy Sponsors:   Kyoto Breast Cancer Research Network;   Pfizer Not yet recruiting

Source: ClinicalTrials.gov - May 31, 2019 Category: Research Source Type: clinical trials